Navigation Links
BD Visispear Eye Sponge

ProductsBD Visispear Eye Sponge
Company BD Ophthalmics
Item BD Visispear Eye Sponge
Features Fast wicking action delivers quick absorption of blood & fluid from the surgical area, The flat tip provides precise application at the surgical incision
Description 
Info BD Ophthalmics
Customer Service: (800) 237-2174
Web site: http://www.bd.com/ophthalmology

Related medicine products :

1. Cylindrical Sponge Implants - 3.0 x 80 mm
2. Olk Design Sponge Implants - 5.0 x 2.5 x 80 mm
3. Olk Design Sponge Implants - 7.5 x 2.75 x 80 mm
4. Cylindrical Sponge Implants - 4.0 x 80 mm
5. Cylindrical Sponge Implants - 5.0 x 80 mm
6. Oval Sponge Implants - 5.5 x 7.5 x 80 mm
7. Grooved Segmental Buckle and Oval Sponge Kits
8. Oval Sponge Implants - 3.0 x 5.0 x 100 mm
9. Storz Supersorb Micro Eye Sponge
10. Ultrafoam Collagen Sponge
11. Goffman Sponge
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products:
(Date:3/4/2015)... SIGVARIS proved innovative when they ... compression therapy collection designed exclusively for men. Building ... is proud to announce the launch of three additional ... from a unique, extremely fine synthetic fiber, MIDTOWN MICROFIBER ... and thigh-highs offer a tailored look that is perfect ...
(Date:3/4/2015)... March 04, 2015 The Alliance ... leaders for its upcoming fifth annual Advanced Therapies ... France. The event this year will feature five ... 20 of the field’s leading companies and organizations. ... top executives and clinical researchers from the advanced ...
(Date:3/4/2015)... 04, 2015 Jeannie Mai, TV personality, fashion ... graces the cover of the print publication. Mai embraces the ... organic when shopping for clothes and personal care products. In ... about her commitment to an organic diet. She mentions, “Having ... only in gymnastics, but also now as I’m a full ...
(Date:3/4/2015)... Francisco, CA (PRWEB) March 04, 2015 ... solutions have been selected by Chase Brexton Health ... company announced today. , Chase Brexton provides comprehensive ... more than 30,000 patients across seven clinics in ... early adopters of electronic medical records, the organization ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 A new ... showing promise in terms of extending life. Studies ... that this new dieting routine can help extend life ... production clearly has long term benefits, many suffering from ... a quicker substitute is necessary. As an alternative to ...
Breaking Medicine News(10 mins):Health News:Building on the Success of MIDTOWN MICROFIBER, SIGVARIS Expands Popular Compression Collection with Longer Foot Length Offerings 2Health News:The Alliance for Regenerative Medicine Announces Agenda for Upcoming Advanced Therapies Summit 2Health News:The Alliance for Regenerative Medicine Announces Agenda for Upcoming Advanced Therapies Summit 3Health News:Chase Brexton Selects i2i Systems Population Health Management Solutions to Demonstrate HEDIS Quality Outcomes to Maryland’s Health Plans 2Health News:Chase Brexton Selects i2i Systems Population Health Management Solutions to Demonstrate HEDIS Quality Outcomes to Maryland’s Health Plans 3Health News:Diet Doc Introduces New Alternative to the Feast and Famine Diet 2Health News:Diet Doc Introduces New Alternative to the Feast and Famine Diet 3
... treatment for sickle cell disease developed at the Los ... 3 clinical trials, David I. Meyer, PhD, LA BioMed ... U.S. have begun administering the sickle cell treatment developed ... LA BioMed and licensed to Emmaus Medical, Inc. The ...
... & Science University Knight Cancer Institute researchers found that the ... acts independently of the HER-2 gene, known to be a ... gene could ultimately help fine-tune a patient,s treatment and enable ... The study, published online this month by Breast Cancer ...
... By Steven Reinberg HealthDay Reporter , THURSDAY, July ... airborne fungus that can cause life-threatening illness -- is an ... Thursday. While C. gattii infections are rare ... they can be severe and even fatal, researchers at the ...
... of the Division of Allergy and Immunology at ... to extend funding of his long-standing investigation into ... the award from the National Institute of Allergy ... record of research accomplishment." Eosinophilic disorders ...
... Hepatitis B virus (HBV) and hepatitis C virus (HCV) ... according to a new study in Gastroenterology , ... Institute. In this study, doctors found that anesthesia contamination ... infection. Efforts are needed to better educate ...
... Calif.) A total joint replacement registry based on ... quality of care, cost-effectiveness and research, according to a ... Clinical Orthopedics and Related Research , a journal ... Kaiser Permanente,s Total Joint Replacement Registry the nation,s ...
Cached Medicine News:Health News:Sickle cell treatment developed at LA BioMed enters Phase 3 clinical trial 2Health News:OHSU Knight Cancer Institute researchers isolate importance of gene in breast cancer prognosis 2Health News:Dangerous Fungus Now Endemic in Pacific Northwest: CDC 2Health News:Dangerous Fungus Now Endemic in Pacific Northwest: CDC 3Health News:Doctor at Cincinnati Children's receives prestigious NIH MERIT Award 2Health News:Misuse of anesthesia could cause hepatitis virus transmission 2Health News:Kaiser Permanente demonstrates success of large-scale total joint replacement registry 2
(Date:3/3/2015)... Actavis plc (NYSE: ACT ) today announced ... aggregate principal amount of senior unsecured notes in 10 ... by its indirect wholly-owned subsidiary, Actavis Funding SCS, and ... as follows: Logo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... , Due 2016 , 100.00% 1.850% Senior ...
(Date:3/3/2015)... 2015  Cumberland Pharmaceuticals Inc. (NASDAQ: ... hospital acute care and gastroenterology, today announced fourth ... revenue grew 15% in 2014 to $37 million, ... $0.35 per diluted share. At the end of ... million including $55 million in cash and investments, ...
(Date:3/3/2015)... March 3, 2015 /CNW/ - The issue: ... a health product being injected at Art Nails Ltd., located at ... to be unauthorized as it contained no labelling. All products administered ... by Health Canada and must have approved labelling. ... been administered to consumers. Potential risks associated with injecting an unauthorized ...
Breaking Medicine Technology:Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 2Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 3Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 4Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 5Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 6Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 7Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 8Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 9Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 10Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 2Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 3Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 4Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 5Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 6Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 7Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 8Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 9Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 10Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 11Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 12Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 13Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 14Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 15Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 16Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 17Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 18Advisory - Health product seized from Art Nails in Vancouver 2